Eur. J. Haematol. 2020 Jan 28
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Ali NA, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, Sallman DA, Cluzeau T
Therapy related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) are defined as complications of previous cytotoxic therapy. Azacitidin ...
Read More
Source: PubMed
Int J Mol Sci
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T, Furstoss N, Savy C, El Manaa W, Zerhouni M, Blot L, Calleja A, Dufies M, Dubois A, Ginet C, Mounier N, Garnier G, Raynaud S, Rohrlich PS, Peterlin P, Stamatoullas A, Chermat F, Fenaux P, Jacquel A, Robert G, Auberger P
Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The le ...
Read More
Source: PubMed
Clin Lymphoma Myeloma Leuk 2019 Nov 26
Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines.
Marcault C, Venton G, Gastaud L, Mannone L, Rey J, D'Incan E, Saillard C, Charbonnier A, Raynaud S, Vey N, Cluzeau T
The standard first-line treatment for acute myeloid leukemia (AML) is a combination of cytarabine and anthracyclines. To date, there is no commonly ag ...
Read More
Source: PubMed
